11:30-12.30

SESSION 3: ACUTE MYELOBLASTIC LEUKEMIA

03 OCTOBER 2019, THURSDAY

Registrations - Coffee

17:00-17:30

17:30-18:00

AHOS 2019-Opening Remarks

Summary of the five previous AHOS: 2014 (Athens), 2015 (Chios), 2016 (Thessaloniki), 2017 (Rhodes), and 2018
(Porto Heli) / Agenda of the 6th AHOS

Guray Saydam,TR - Evangelos Terpos,GR

18:00-19:30

SESSION 1: MYELODYSPLASTIC SYNDROMES

Osman Ilhan,TR - Nora-Athina Viniou,GR

Moderators:

Debate:

NGS in the diagnosis and prognosis of MDS

Speaker:

Yes: Mehmet Ali Ozcan,TR

No: Georgia Kaiafa,GR

Lecture:

Speaker:

Treatment of lower risk MDS after the failure of ESAS

Vassiliki Pappa,GR

Moderator:

Meltem Aylı,TR

Speaker:

Itır Demiriz Şirinoğlu,TR

20:15

Opening Ceremony - Welcome Reception

04 OCTOBER 2019, FRIDAY

Ant Uzay, TR

Speaker:

Sami Kartı, TR

Moderator:

Meral Beksac,TR

Double ASCT: Suitable for all patients

Speaker:

Lecture:

Efstathios Kastritis,GR

Speaker:

What is the optimal number of cycles for induction pre-ASCT?

Lecture:

Moderators:

Hayri Ozsan,TR - Evangelos Terpos,GR

09:00-10:30

SESSION 2: Common Symposium of Balkan Myeloma Study Group and AHOS: Practical Considerations for Frontline Therapy

10:30-11:00

Satellite Symposium (sponsored by Amgen):

New Era with Carfilzomib in the Treatment of Relapsed Multiple Myeloma

11:00-11:30

Coffee Break

Moderators:

Maria Pagoni, GR – Nil Güler, TR

Debate:

High or low intensity therapy for elderly AML patients?

Speakers:

High Intensity: Mehmet Yilmaz, TR

Low Intensity: Sotiris Papageorgiou, GR

Moderator:

Fahri Sahin, TR

Speaker:

Omur Gokmen Sevindik, TR

12:30-13:00

Meet the Expert - 1: Iron Chelation in Myelodysplastic Syndromes

Moderator:

Speaker:

Stavroula Giannouli, GR

Argiris Symeonidis, 

13:00-13:30

Immunomodulatory Drugs in Fit and Unfit Relapsed Refractory Multiple Myeloma 

Moderator:

Speaker:

Pavlina Konstantinidou, GR

Damianos Sotiropoulos, GR

13:30-14:00

Meet the Expert - 2: Multidrug resistant bacteria in Hematology Clinics and BMT Units: a very serious problem all
over the world

Moderators:

Erdal Kurtoglu, TR – Elisavet Grouzi, GR  - Maria Kotsopoulou, GR 

(posters 1-16)

Moderators:

İsmet Aydoğdu,TR – Anastasia Pouli, GR - Nikolaos Giannakoulas, GR

(posters 17-32)

14:00-15:00

Lunch Break

SCIENTIFIC PROGRAM

19:30-20:00

Tretament of benign platelet disorders

15:00-16:00

Poster Session 1 - Poster View and Discussion

16:00-17:00

Poster Session 2 - Poster View and Discussion

16:00-17:00

Oral Session 1 

17:00-18:30

SESSION 4: NON-HODGKIN’S LYMPHOMA

Zahit Bolaman, TR – Nikos Harhalakis, GR

Moderators:

Should eligible patients with T-cell lymphoma receive high-dose therapy and autologous stem cell
transplant in the upfront setting

Debate:

Yes: Maria Angelopoulou, GR

No: Elif Birtas, TR

Speakers:

Modern Management of Follicular Lymphoma: Focus on First Relapse

Lecture:

Marie-Christine Kyrtsonis, GR

Speaker:

19:15-20:15

Satellite Symposium (sponsored by Jannsen):

Ibrutinib in MCL and CLL

Moderators:

Levent Ündar, TR - Şeniz Öngören, TR

Speakers:

MCL: Burhan Ferhanoglu, TR
CLL: Ozan Salim, TR

05 OCTOBER 2019, SATURDAY

16:00-17:00

Poster Session 2 - Poster View and Discussion

Speaker:

Moderators:

Moderators:

Güray Saydam, TR 

Lecture:

Pre-clinical and clinical development of Nivolumab

Meltem Olga Akay, TR

12:30-13:30

Satellite Symposium (Sponsered by BMS) :

Nivolumab in Relapsed Refractory Hodgkin’s Lymphoma

Lecture:

Scientific data of efficacy of Nivolumab in RRHL

Speaker:

Tulin Firatli Tuglular, TR

Moderator:

Evangelos Terpos, GR

Eirini Katodritou, GR

Speaker:

Moderator:

Kostas Konstantopoulos, GR - Atilla Özkan, Tr

Speaker:

Theodoros Vassilakopoulos, GR

14:00-15:00

Lunch Break

13:30-14:00

Lecture : Novel Proteasome Inhibitors and IMiDs combinations for Multiple Myeloma

Cengiz Ceylan, TR – Kyriaki Kokoviadou, GR – Pavlina Marinaki, GR (posters 33-48)

15:00-16:00

Poster Session 1 - Poster View and Discussion

10:30-11:15

SESSION 6: Transplantation

Moderators:

Zafer Gulbas, TR – Ioanna Sakellari, GR

Allo-BMT in all eligible AML FLT3+, MPN1+ patients: Yes or No

Debate:

Speakers:

YES: Mutlu Arat, TR
NO: Ioannis Baltadakis,GR

Panayiotis Panayiotidis, GR – Fahri Sahin, TR

Moderators:

Speaker:

Jane Apperley, UK

11:15-11:45

Coffee Break

11:45-12:30

Invited Speaker by the Organizing Universities

16:00-17:00

Oral Session 2

17:00-17:30

Meet the Expert-3: How I treat Mediastinal Large B-cell Lymphoma?

Moderators:

Despina Mparmparoussi, GR – Duzgun Ozatli,TR 

Moderators:

Emin Kaya, TR  – Anna Kioumi, GR – Emmanouel Spanoudakis, GR (posters 49-64)

Moderators:

Μaria Gavriatopoulou, GR - Mahmut Tobu, TR 

Moderators:

Ridvan Ali, TR -  Gulsum Ozet, TR 

Lecture:

PNH: Update and current status

Speaker:

Asu Fergün Yılmaz, TR

Lecture:

Improvement of anti-CD20 MoAb: Obinituzumab

Speaker:

Ümit Yavuz Malkan,TR

Lecture:

Efficay and safety of obinituzumab in CLL

Speaker:

Birol Guvenc, TR

17:30-19:00

PNH and New MoAbs in CLL and NHLs

19:00-19:45

Invited speaker by the Co-Chairs

06 OCTOBER 2019, SUNDAY

Guray Saydam,TR - Evangelos Terpos,GR

Moderators:

Lecture:

Speaker:

Mechanisms of cardiotoxicity of novel anticancer drugs

Ioanna Andreadou,GR

19:45-20:00

Best presentations Ceremony

Guray Saydam,TR - Evangelos Terpos,GR

Speaker:

Sosana Delimpasi,GR

Maintenance therapy: which drug and for how long

Lecture:

Lecture:

Ph like ALL

Speaker:

Maria Papaioannou, GR

YES: Sinem Civriz Bozdag, TR
NO: Panagiotis Tsirigotis, GR

Speakers:

Chemotherapy free strategy for ph+ ALL?

Debate:

Filiz Vural, TR – Ioannis Kotsianidis, GR

Moderators:

Moderator:

Ali Unal, Tr

Tayfur Toptaş, Tr

Speaker:

18:30-19:15

Monoclonal Antibodies in the treatment of ALL

1-Nivolumab For Relapsed Or Refractory Hodgkin Lymphoma: Real-Life Experience

(Burhan Ferhanoglu et al, Istanbul,Turkey)

 

2-Incidence And Treatment Outcome Of Lymphomas In Hiv-Infected Patients: The Greek Experience

(Panagiotis Tsirigotis et al, Chaidari,Greece)

 

3-Audiologic Assessment in Patients with Beta Thalassemia Major Receiving Chelating Regimens in Denizli State Hospital: Single Center Experience

(Gulsum Akgun Cagliyan et al,  Denizli,Turkey)

4-Modulation of the IL-6/STAT3 Signaling Axis in CD4+ T Cells as a Potential Immune Mechanism of Action of Azacytidine in High-Risk Myelodysplastic Syndromes.

(Eleftheria Lamprianidou et al, Alexandroupolis, Greece)

 

5-Investigation Of The Effects Of Antifungal Drugs On Cyclosporin Blood Level In Patients With Allogeneic Stem Cell Transplantation: Single Center Experience

(Ayşe Günay et al, Kayseri, Turkey

 

6-Stereotyped Subsets #2 and #169: High Order Sequence Relatedness In The Immunoglobulin Repertoire of CLL

(Katerina Gemenetzi et al, Thessaloniki, Greece)

1-Long-term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-center Real-life Experience

(Burhan Ferhanoglu et al, Istanbul,Turkey)

 

2-Newly Diagnosed Patients With Multiple Myeloma Receiving Asct And Consolidation With Carfilzomib, Lenalidomide And Dexamethasone (Krd) Show High Rates Of Minimal Residual Disease Negativity

(Maria Gavriatopoulou et al, Athens, Greece)

 

3-A Glance to Infectious and Immune Complications During the Course of Chronic Lymphocytic Leukemia: Single Center Experience

(Zehra Narli Ozdemir et al, Ankara, Turkey)

 

4-Three tRNA-Derived RNA Fragments (3′-tRF-LeuAAG/TAG, i-tRF-GluCTC, and i-tRF-ProTGG) Discriminate Smoldering from Symptomatic Multiple Myeloma Patients

(Aristea-Maria Papanota et al, Athens, Greece)

 

5-The Evaluation Of The Clinicopathologic Characteristics Of T-Cell Non-Hodgkin's Lymphoma: A Multicenter Experience

(Elifcan Aladag et al, Ankara, Turkey)

 

6-Rituximab-Dose-Adjusted-Epoch (R-Da-Epoch) In Primary Mediastinal Large B-Cell Lymphoma (Pmlbcl): The Combined Greek And Turkish Real-Life Experience On Outcomes And Prognostic Factors

(Vassilakopoulos TP et al,  Athens Greece)

09:00-10:00

Oral Session 3

Moderators:

10:00-11:00

Oral Session-4

Emre Eşkazan, TR - Nur Soyer, TR 

Moderators:

Mehmet Sonmez, TR - Irfan Yavasoglu, TR 

11:00-11:15

Closing Remarks

1-Retrospective Evaluation Of Clinical And Laboratory Characteristics Of Patients With Folicular Lymphoma

(Hasan Çağrı Yıldırım et al, İzmir, Turkey)

 

2-Paroxysmal Nocturnal Hemoglobinuria Clone In Patients With Refractory Anemia

(Demet Cekdemir et al, İzmir, Turkey)

 

3-Splenic Marginal Zone Lymphoma; Single Center Experience

(Hale Bülbül et al, İzmir, Turkey)

 

4-Ibrutinib As Monotherapy For Relapsed Or Refractory Diffuse Large B Cell Lymphoma Patients: A Single Center Experience

(Sumeyye Balta et al, Elazığ, Turkey)

 

5-Loss Of Early Response With Midostaurine: A Case With Aggressive Systemic Mastocytosis

(Ayşe Uysal et al, Balıkesir, Turkey)

1-Pomalidomide For Relapsed/Refractory Multiple Myeloma : A Single Center Retrospective Study

(Serkan Ünal et al, Kocaeli, Turkey)

 

2-Evaluation of Patients with Adult Onset Langerhans Cell Histiocytosis: A Single Center Experience

(Onur Aşık et al, Kayseri, Turkey)

 

3-Ibrutinib In B-Cell Lymphomas And Chronic Graft Versus Host Disease: A Single Center Experience

(Aysenur Arslan et al, İzmir, Turkey)

 

4-Single Center Experience: Retrospective Evaluation of Patients with Primary Mediastinal Large B-Cell Lymphoma

(Zeynep Tuğba Güven et al, Kayseri, Turkey)

 

5-Nivolumab Treatment For Hodgkin Lymphoma: Ege Hematology Experience

(Fatma Keklik Karadağ et al, İzmir, Turkey

 

6-Response Of Ruxolitinib To Reduce Spleen Size And Other Effectors Of This Response, One Centre Experience

(Aydan Akdeniz et al, Mersin, Turkey)

Eirini Katodritou,GR – Fahri Sahin,TR

09:00-10:30

SESSION 5: ACUTE LYMPHOBLASTIC LEUKEMIA